Position in OMER
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,112,000
+$930,016 QoQ
Shares Held
200,000
+190.7% QoQ
Ownership
0.276%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OMER Over Time
Shares Held
Position Value (USD)
Derivatives in OMER
reported options exposure · as of Dec 31, 2025CallValue
$3,436,000
CallShares
200,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Polar Asset Management Partners Inc. holds $46,847,679 across 13 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
322,467 | $42,801,044 | |
| 2 | RNA |
Atrium Therapeutics, Inc.
|
150,000 | $2,017,500 | |
| 3 | RANI |
Rani Therapeutics Holdings, Inc.
|
2,318,542 | $1,762,091 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,908 | $267,044 | |
| 5 | 1,150,300 | $0 | |||
| 6 | 320,529 | $0 | |||
| 7 | OSRH |
OSR Health, Inc.
|
360,000 | $0 | |
| 8 | ASBP |
Aspire Biopharma Holdings, Inc.
|
138,536 | $0 |
All Filings in OMER
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,112,000 | 200,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,181,984 | 68,800 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $3,436,000 | 200,000 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $6,144,202 | 1,498,586 | Shares | Sole | 2025-12-01 | |
| 2025-09-30 | $5,633,810 | 1,374,100 | Call | Sole | 2025-12-01 | |
| No filing history on record for this holder in this stock. | ||||||